Search Results - "SALAZAR, D. E"

Refine Results
  1. 1

    Cytochrome P450 3A Inhibition by Ketoconazole Affects Prasugrel and Clopidogrel Pharmacokinetics and Pharmacodynamics Differently by Farid, N A, Payne, C D, Small, D S, Winters, K J, Ernest, C S, Brandt, J T, Darstein, C, Jakubowski, J A, Salazar, D E

    Published in Clinical pharmacology and therapeutics (01-05-2007)
    “…Prasugrel and clopidogrel inhibit platelet aggregation through active metabolite formation. Prasugrel's active metabolite (R‐138727) is formed primarily by…”
    Get full text
    Journal Article
  2. 2

    A simple assay to study social behavior in Drosophila: measurement of social space within a group by Simon, A F, Chou, M-T, Salazar, E D, Nicholson, T, Saini, N, Metchev, S, Krantz, D E

    Published in Genes, brain and behavior (01-03-2012)
    “…We have established a new simple behavioral paradigm in Drosophila melanogaster to determine how genes and the environment influence the behavior of flies…”
    Get full text
    Journal Article
  3. 3

    The Use of Modeling and Simulation to Guide Clinical Development of Olmesartan Medoxomil in Pediatric Subjects by Salazar, D E, Song, S H, Shi, J, Rohatagi, S, Heyrman, R, Wada, D R, Carrothers, T J

    Published in Clinical pharmacology and therapeutics (01-02-2012)
    “…Modeling and simulation were used extensively in the development of an indication for the use of olmesartan medoxomil in pediatric patients with hypertension…”
    Get full text
    Journal Article
  4. 4

    Effect of rifampin on the pharmacokinetics and pharmacodynamics of prasugrel in healthy male subjects by Farid, N. A., Jakubowski, J. A., Payne, C. D., Li, Y. G., Jin, Y., Ernest, C. S., Winters, K. J., Brandt, J. T., Salazar, D. E., Small, D. S.

    Published in Current medical research and opinion (01-08-2009)
    “…ABSTRACT Objective: Prasugrel is a thienopyridine antiplatelet agent for the prevention of atherothrombotic events in patients with acute coronary syndrome…”
    Get full text
    Journal Article
  5. 5

    Pharmacokinetics and pharmacodynamics of prasugrel in subjects with moderate liver disease by Small, D. S., Farid, N. A., Li, Y. G., Ernest II, C. S., Winters, K. J., Salazar, D. E., Payne, C. D.

    “…Summary Background and Objective:  Prasugrel is a thienopyridine antiplatelet agent under investigation for the prevention of atherothrombotic events in…”
    Get full text
    Journal Article
  6. 6

    Induction of cytochrome P450IIE1 in the obese overfed rat by Raucy, J L, Lasker, J M, Kraner, J C, Salazar, D E, Lieber, C S, Corcoran, G B

    Published in Molecular pharmacology (01-03-1991)
    “…Cytochrome P450IIE1 (IIE1) is a microsomal xenobiotic-activating enzyme that is inducible not only by various chemical agents but also by fasting and diabetes…”
    Get more information
    Journal Article
  7. 7

    Prasugrel pharmacokinetics and pharmacodynamics in subjects with moderate renal impairment and end-stage renal disease by Small, D. S., Wrishko, R. E., Ernest II, C. S., Ni, L., Winters, K. J., Farid, N. A., Li, Y. G., Brandt, J. T., Salazar, D. E., Borel, A. G., Kles, K. A., Payne, C. D.

    “…Objective:  The pharmacokinetic (PK) and pharmacodynamic (PD) responses to prasugrel were compared in three studies of healthy subjects vs. those with moderate…”
    Get full text
    Journal Article
  8. 8

    Coadministration of nefazodone and benzodiazepines. III: A pharmacokinetic interaction study with alprazolam by GREENE, D. S, SALAZAR, D. E, DOCKENS, R. C, KROBOTH, P, BARBHAIYA, R. H

    Published in Journal of clinical psychopharmacology (01-12-1995)
    “…This study was conducted to determine the potential for an interaction between nefazodone, a new antidepressant, and alprazolam after single- and multiple-dose…”
    Get full text
    Journal Article
  9. 9

    Predicting creatinine clearance and renal drug clearance in obese patients from estimated fat-free body mass by Salazar, D E, Corcoran, G B

    Published in The American journal of medicine (01-06-1988)
    “…Existing methods for predicting creatinine clearance provide accurate estimates for normal-weight patients but not for patients who are obese. Studies into…”
    Get more information
    Journal Article
  10. 10

    Carbamazepine-nefazodone interaction in healthy subjects by LAROUDIE, C, SALAZAR, D. E, COSSON, J.-P, CHEUVART, B, ISTIN, B, GIRAULT, J, INGRAND, I, DECOURT, J.-P

    Published in Journal of clinical psychopharmacology (01-02-2000)
    “…The pharmacokinetic interaction between nefazodone and carbamazepine was investigated in 12 healthy male volunteers. Subjects received nefazodone 200 mg twice…”
    Get full text
    Journal Article
  11. 11

    Pharmacokinetic evaluation of co-administration of nefazodone and lithium in healthy subjects by LAROUDIE, C, SALAZAR, D. E, COSSON, J.-P, CHEUVART, B, ISTIN, B, GIRAULT, J, INGRAND, I, DECOURT, J.-P

    Published in European journal of clinical pharmacology (01-02-1999)
    “…To evaluate the possible pharmacokinetic interaction between nefazodone and lithium. Twelve healthy volunteers received nefazodone 200 mg b.i.d. for 5 days. A…”
    Get full text
    Journal Article
  12. 12

    Coadministration of nefazodone and benzodiazepines. I: Pharmacodynamic assessment by KROBOTH, P. D, FOLAN, M. M, LUSH, R. M, CHAIKIN, P. C, SHUKLA, U. A, RASHMI BARBHAIYA, SALAZAR, D. E

    Published in Journal of clinical psychopharmacology (01-10-1995)
    “…One hundred two healthy men were evaluated in one of three studies conducted to evaluate the coadministration of nefazodone, 200 mg twice daily, and three…”
    Get full text
    Journal Article
  13. 13

    Monitoring of Acute Migraine Attacks: Placebo Response and Safety Data by Jhee, Stanford S., Salazar, Daniel E., Ford, Neville F., Fulmor, I. Edgar, Sramek, John J., Cutler, Neal R.

    Published in Headache (01-01-1998)
    “…In the course of evaluating the safety and efficacy of an investigational compound for acute migraine headaches, a large number of patients received placebo at…”
    Get full text
    Journal Article
  14. 14

    Evaluation of cerebral pharmacokinetics of the novel antidepressant drug, BMS-181101, by positron emission tomography by Christian, B T, Livni, E, Babich, J W, Alpert, N M, Dischino, D D, Ruediger, E, Salazar, D E, Ford, N F, Fischman, A J

    “…BMS-181101 is a novel antidepressant drug that is currently under clinical investigation. The goal of this study was to evaluate the pharmacokinetics and…”
    Get more information
    Journal Article
  15. 15
  16. 16

    Pharmacokinetics, Tolerability, and Safety of Aripiprazole following Multiple Oral Dosing in Normal Healthy Volunteers by Mallikaarjun, Suresh, Salazar, Daniel E., Bramer, Steven L.

    Published in Journal of clinical pharmacology (01-02-2004)
    “…Two 14‐day, placebo‐controlled, double‐blind studies evaluated the fasting pharmacokinetics, safety, and tolerability of aripiprazole, a new antipsychotic, in…”
    Get full text
    Journal Article
  17. 17

    Obesity as a risk factor in drug-induced organ injury. IV. Increased gentamicin nephrotoxicity in the obese overfed rat by Corcoran, G B, Salazar, D E

    “…Obese humans suffer from excessive organ dysfunction, altered drug pharmacokinetics and may be at increased risk of various drug toxicities. A recent report…”
    Get more information
    Journal Article
  18. 18

    Pharmacokinetics and Pharmacodynamics of Avitriptan in Patients With Migraine After Oral Dosing by Cutler, Neal R., Salazar, Daniel E., Jhee, Stanford S., Fulmor, I. Edgar, Ford, Neville, Smith, Robert A., Sramek, John J.

    Published in Headache (01-06-1998)
    “…Avitriptan (BMS‐180048) is a 5‐HT1‐like receptor agonist for the treatment of migraine. This double‐blind, placebo‐controlled, randomized, parallel‐group study…”
    Get full text
    Journal Article
  19. 19

    Coadministration of nefazodone and benzodiazepines. IV: A pharmacokinetic interaction study with lorazepam by GREENE, D. S, SALAZAR, D. E, DOCKENS, R. C, KROBOTH, P, BARBHAIYA, R. H

    Published in Journal of clinical psychopharmacology (01-12-1995)
    “…This study was conducted to determine the potential for an interaction between nefazodone (NEF), a new antidepressant, and lorazepam (LOR) after single- and…”
    Get full text
    Journal Article
  20. 20

    A Pharmacokinetic-Pharmacodynamic Model of d-Sotalol Q-Tc Prolongation During Intravenous Administration to Healthy Subjects by Salazar, Daniel E., Much, David R., Nichola, Peter S., Seibold, James R., Shindler, Daniel, Slugg, Peter H.

    Published in Journal of clinical pharmacology (01-09-1997)
    “…The objective of this study was to assess the pharmacokinetics and pharmacodynamics of the dextro (d‐) isomer of sotalol, a class III antiarrhythmic agent, in…”
    Get full text
    Journal Article Conference Proceeding